CAS 107233-08-9|Cevimeline

Introduction：Basic information about CAS 107233-08-9|Cevimeline, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Cevimeline BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Cevimeline
CAS Number	107233-08-9	Molecular Weight	199.31
Density	1.2±0.1 g/cm3	Boiling Point	308.5±42.0 °C at 760 mmHg
Molecular Formula	C₁₀H₁₇NOS	Melting Point	195-197ºC
MSDS	/	Flash Point	140.4±27.9 °C

Names

Name	cevimeline
Synonym	More Synonyms

Cevimeline BiologicalActivity

Description	Cevimeline (Evoxac) is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors; used in the treatment of dry mouth associated with sjogren's syndrome.IC50 value:Target: M3 receptor
Related Catalog	Signaling Pathways >>GPCR/G Protein >>mAChRSignaling Pathways >>Neuronal Signaling >>mAChRResearch Areas >>Neurological Disease
References	[1]. Witsell DL, et al. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia.Head Neck. 2012 Aug;34(8):1136-42. doi: 10.1002/hed.21894. Epub 2012 Jan 9. [2]. Ono K, et al. Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats.Arch Oral Biol. 2012 Apr;57(4):421-8. Epub 2011 Nov 17. [3]. Kondo Y, et al.Cevimeline-induced monophasic salivation from the mouse submandibular gland: decreased Na+ content in saliva results from specific and early activation of Na+/H+ exchange.J Pharmacol Exp Ther. 2011 Apr;337(1):267-74. Epub 2011 Jan 14. [4]. Voskoboynik B, et al.Cevimeline (Evoxac) overdose.J Med Toxicol. 2011 Mar;7(1):57-9. [5]. Tajiri S, et al. Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations.Int J Pharm. 2010 Jan 4;383(1-2):99-105. Epub 2009 Sep 10.

Description

Cevimeline (Evoxac) is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors; used in the treatment of dry mouth associated with sjogren's syndrome.IC50 value:Target: M3 receptor

Related Catalog

Signaling Pathways >>GPCR/G Protein >>mAChRSignaling Pathways >>Neuronal Signaling >>mAChRResearch Areas >>Neurological Disease

References

[1]. Witsell DL, et al. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia.Head Neck. 2012 Aug;34(8):1136-42. doi: 10.1002/hed.21894. Epub 2012 Jan 9.

[2]. Ono K, et al. Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats.Arch Oral Biol. 2012 Apr;57(4):421-8. Epub 2011 Nov 17.

[3]. Kondo Y, et al.Cevimeline-induced monophasic salivation from the mouse submandibular gland: decreased Na+ content in saliva results from specific and early activation of Na+/H+ exchange.J Pharmacol Exp Ther. 2011 Apr;337(1):267-74. Epub 2011 Jan 14.

[4]. Voskoboynik B, et al.Cevimeline (Evoxac) overdose.J Med Toxicol. 2011 Mar;7(1):57-9.

[5]. Tajiri S, et al. Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations.Int J Pharm. 2010 Jan 4;383(1-2):99-105. Epub 2009 Sep 10.

Chemical & Physical Properties

Density	1.2±0.1 g/cm3
Boiling Point	308.5±42.0 °C at 760 mmHg
Melting Point	195-197ºC
Molecular Formula	C₁₀H₁₇NOS
Molecular Weight	199.31
Flash Point	140.4±27.9 °C
PSA	37.77000
LogP	1.23
Vapour Pressure	0.0±0.7 mmHg at 25°C
Index of Refraction	1.586
InChIKey	WUTYZMFRCNBCHQ-HTLJXXAVSA-N
SMILES	CC1OC2(CS1)CN1CCC2CC1
Storage condition	-20°C

Synonyms

3]oxathiolane]

CevimelineHClSalt

CEVIMELINE, HYDROCHLORIDE SALT

(2R,2'R)-2'-Methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane]

cis-2'-Methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane]

Evoxac

AF-102B

(2R,2'R)-2'-Methylspiro[4-azabicyclo[2.2.2]octan-2,5'-[1,3]oxathiolan]

(2R,2'R)-Cevimeline

Cevimeline

(2R,2'R)-rel-2'-Methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane]

3R)-rel

Spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-, (2'R,3R)-

SNI-2011

Recommended......